RSS Feeds
Inhaled Corticosteroids or Antileukotrienes for Asthma?
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
Dr. Hampson suggests that inhaled corticosteroids are a better treatment for asthma than montelukast. Although he correctly points out that, in our study, the mean response of inhaled beclomethasone was larger for some end points, he neglects to mention the important aspect of our analysis: the response distribution. Mean values frequently provide less clinical information than a clear understanding of response distributions. For example, our report clearly demonstrates how these two therapies largely overlap in their response distributions for the FEV1 end point. In addition, with regard to the clinically important outcome of the prevention of worsening asthma episodes (attacks), both therapies significantly differed from placebo and were not different from each other.
With a once-daily oral medication such as montelukast, greater real-world compliance may translate into even greater real-world effectiveness.
- Copyright ©2004 by the American College of Physicians
